Clinical trials · Texas
Locally Advanced (Unresectable) or Metastatic Solid Tumors clinical trials in Texas
We’re tracking 525 recruiting locally advanced (unresectable) or metastatic solid tumors studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT07416123RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests an experimental drug, GEN1106, for people with solid tumors that have not responded to standard treatments. It aims to see if the drug can help shrink or control the cancer.
San Antonio, TexasAges 18 years+ - NCT05417594RecruitingPhase 1/Phase 2
Targeted drug study for advanced cancers with genetic changes
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
Houston, TexasAges 18–130 - NCT07703878RecruitingPhase 1
A study of GS-1206 for people with solid tumors
This trial tests a new drug called GS-1206 for adults with solid tumors that have a specific genetic change. It aims to see if the drug is safe and can shrink or slow the growth of the cancer after other treatments have stopped working.
Austin, TexasAges 18 years+ - NCT06028074RecruitingPhase 1/Phase 2
Study of GIM-122 for advanced solid tumors
This trial tests a new drug, GIM-122, in people with advanced solid tumors that have stopped responding to or cannot tolerate standard PD-1/PD-L1 inhibitors. The goal is to see if GIM-122 is safe and tolerable.
Dallas, TexasAges 18 years+ - NCT05405595RecruitingPhase 1/Phase 2
Study drug with pembrolizumab for advanced solid tumors
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
Houston, TexasAges 18 years+ - NCT06217822RecruitingPhase 1
Testing a new radiation therapy for advanced prostate cancer
This trial tests a new radioactive drug, 225Ac-PSMA-Trillium, that targets prostate cancer cells. It is for people whose advanced prostate cancer has stopped responding to hormone therapy and may have spread.
Houston, TexasAges 18 years+ - NCT07141706RecruitingPhase 1
Testing DB-1317 in advanced solid tumors
This trial tests an investigational drug (DB-1317) that targets a protein called ADAM9, found on some solid tumors. It is for people with advanced cancers that have not responded to other treatments, and aims to see if the drug is safe and works.
Houston, TexasAges 18 years+ - NCT04469530RecruitingPhase 2
Sirolimus plus low-dose chemotherapy for high-risk childhood tumors
This Phase 2 study tests whether sirolimus combined with low-dose (“metronomic”) chemotherapy can help children and young adults with certain high-risk solid tumors stay in remission or reduce recurrence risk. It is designed for people whose cancer has responded well to initial treatment, with only minimal or no visible disease on scans.
Houston, TexasAges 1–30 - NCT06651593RecruitingPhase 2
BND-22 and cemiplimab for advanced solid tumors
This trial tests a combination of two new drugs, BND-22 and cemiplimab, for people with certain advanced solid tumors like lung, colorectal, or ovarian cancer. It aims to see if this treatment helps control the cancer and looks at specific markers in your blood and tissue.
Houston, TexasAges 18 years+ - NCT05701527RecruitingPhase 1
EBC-129 for advanced solid tumors with limited treatment options
This Phase 1 study tests EBC-129, a new investigational treatment, in people with advanced solid tumors that cannot be fully removed and have limited or no good standard treatment options. The goal is to learn if the treatment is safe, find helpful dosing, and see signs it may slow the cancer.
Houston, TexasAges 18 years+ - NCT06504368RecruitingPhase 1
Testing a new drug DCR-PDL1 for advanced solid tumors
This trial tests an experimental drug called DCR-PDL1 for people with advanced solid tumors or non-Hodgkin's lymphoma that has not responded to, progressed on, or could not tolerate standard treatments, or for which no standard treatment exists. The goal is to see if it is safe and how the body processes it.
San Antonio, TexasAges 18 years+ - NCT06265727RecruitingPhase 1/Phase 2
Study of CRB-701 for solid tumors with nectin-4
This trial tests a new drug, CRB-701, for people with advanced solid tumors that have a protein called nectin-4 on their surface. It might be an option if other treatments have stopped working or are not available.
Tyler, TexasAges 18 years+ - NCT06963281RecruitingPhase 1
Study of an experimental drug for late-stage solid tumors
This trial tests an experimental drug called IBI3020 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for these patients.
Irving, TexasAges 18–75 - NCT06563375RecruitingPhase 1
Testing NP-101 for advanced solid tumors
This trial tests a new drug called NP-101 for people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and see if it can shrink tumors.
Houston, TexasAges 18 years+ - NCT07436728RecruitingPhase 1/Phase 2
Study of TAK-505 for adults with solid tumors
This trial tests TAK-505, an experimental drug, for people with advanced solid tumors including lung, colorectal, stomach, or head and neck cancers. It aims to see if the drug can help when standard treatments are no longer working or aren't suitable.
San Antonio, TexasAges 18 years+ - NCT07359820RecruitingPhase 2
Lirafugratinib for solid tumors with FGFR2 fusion
This trial tests a targeted drug called lirafugratinib for people with advanced solid tumors (not bile duct cancer) that have a specific FGFR2 gene change. The drug blocks the faulty protein from helping the cancer grow.
Houston, TexasAges 18 years+ - NCT07175441RecruitingPhase 2
Testing a new drug combo for advanced liver cancer
This trial tests a new drug called RBS2418 added to two immunotherapy medicines (tremelimumab and durvalumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination helps patients who are starting their first treatment for this stage of liver cancer.
Dallas, TexasAges 18 years+ - NCT06885281RecruitingPhase 1/Phase 2
Study of ZL-1310 for neuroendocrine carcinoma
This trial is testing an experimental drug called ZL-1310 for people with neuroendocrine carcinoma (a rare, fast-growing cancer) that has spread or can't be removed. It aims to see if the drug is safe and works against the cancer.
Dallas, TexasAges 18 years+ - NCT07095868RecruitingPhase 1/Phase 2
Study of EVM14 for advanced solid tumors
This trial tests a new drug called EVM14, alone or with other treatments, for people with advanced solid tumors that can't be removed by surgery or have spread. It aims to see if the drug is safe and helps shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT04796012RecruitingPhase 1/Phase 2
Atezolizumab plus chemo for children with recurrent solid tumors
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
Dallas, TexasAges 6 months–30 years - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Houston, TexasAges 18 years+ - NCT05379595RecruitingPhase 1/Phase 2
Amivantamab for advanced colon or rectal cancer with specific tumor traits
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
Houston, TexasAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Conroe, TexasAges 18 years+ - NCT06010342RecruitingPhase 2
TL118 for solid tumors with NTRK fusion
This trial tests an experimental pill called TL118 for people whose solid tumors have a specific NTRK gene fusion. It aims to see if the drug can shrink tumors or slow their growth when other treatments have stopped working or aren't an option.
Houston, TexasAges 18 years+
Locally Advanced (Unresectable) or Metastatic Solid Tumors trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting locally advanced (unresectable) or metastatic solid tumors studies listed above.
- The University of Texas MD Anderson Cancer Center · 13 studies
- NEXT Oncology · 5 studies
- Texas Oncology · 3 studies
- Baylor College of Medicine · 2 studies
- Texas Children's Hospital · 2 studies
- University of Texas Southwestern Medical Center · 2 studies
- Ben Taub General Hospital
- Mary Crowley Cancer Center
What taking part in a locally advanced (unresectable) or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there locally advanced (unresectable) or metastatic solid tumors clinical trials in Texas?
- Yes. We're currently tracking 525 recruiting locally advanced (unresectable) or metastatic solid tumors studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a locally advanced (unresectable) or metastatic solid tumors study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a locally advanced (unresectable) or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New locally advanced (unresectable) or metastatic solid tumors studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.